Abbreviated name: D3 L-DOPA
Synonyms: DP-102
Compound class:
Synthetic organic
Comment: Chronic treatment with a substantially lower dose of deuterium-substituted L-DOPA (D3-L-DOPA), compared with L-DOPA (levodopa) produced equal anti-parkinsonian effects and reduced dyskinesia in 6-OHDA-lesioned rats [2]. This new rat study reports similar effect produced by D3-L-DOPA and selegiline plus L-DOPA, respectively, implying adjuvant MAO-B inhibitor treatment may not be necessary with D3-L-DOPA [1]. This compound was proposed for development by the Michael J Fox foundation but there is no ClinicalTrials.gov entry.
|
|
References |
1. Malmlöf T, Feltmann K, Konradsson-Geuken Å, Schneider F, Alken RG, Svensson TH, Schilström B. (2015)
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor. J Neural Transm, 122 (2): 259-72. [PMID:24906468] |
2. Malmlöf T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilström B. (2010)
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias. Exp Neurol, 225 (2): 408-15. [PMID:20659451] |